FDA rejects Capricor's Duchenne cell therapy deramiocel a second time, citing trial data issues

Capricor said it received a second Complete Response Letter for its biologics license application, despite narrowing the requested indication; Endpoints News reports the FDA cited significant issues with the trial, and shares fell about 70% after hours.
Why it matters
Deramiocel is an allogeneic cardiosphere-derived cell therapy that Capricor was seeking to approve for Duchenne muscular dystrophy, first for cardiomyopathy and then, after an earlier rejection, a narrower indication. The second Complete Response Letter ends the current application and wiped out most of the company's value after hours. Duchenne advocacy groups called the decision devastating. Endpoints reports the FDA cited significant issues with the trial, and a July advisory panel had voted against the data. Watch for Capricor's plan for a new trial or appeal, and for the FDA's published letter.
Key facts
- Second Complete Response Letter for the deramiocel BLA, announced Friday
- Indication had been narrowed before this decision
- Shares fell about 70% after hours (X reports 68–77%)
- Endpoints: FDA cited significant issues with the trial
- Parent Project Muscular Dystrophy called it devastating news